cancer vaccines a primer...summary points • rna-based poly-neoepitope individualized mutanome...
TRANSCRIPT
![Page 1: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/1.jpg)
DR TOH HAN CHONG DEPUTY DIRECTOR
NATIONAL CANCER CENTRE SINGAPOREASSOCIATE PROFESSOR
DUKE-NUS MEDICAL SCHOOL
CANCER VACCINES – A PRIMER
![Page 2: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/2.jpg)
WHAT ARE VACCINES?
![Page 3: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/3.jpg)
The Immune System Fights Cancer
![Page 4: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/4.jpg)
HOW CANCER
VACCINES WORK
![Page 5: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/5.jpg)
INFUSE
PATIENT
APC takes
up the
antigen
Recombinant
Prostatic Acid
Phosphatase (PAP)
antigen+GM-CSF
fusion protein binds to
resting antigen
presenting cell (APC)
Fully activated,
the APC is now
Sipuleucel-T
Antigen is
processed and
presented on
surface of the APC
T-cells proliferate and attack
cancer cells
Sipuleucel-T activates
T-cells in the body
Active
T-cellInactive
T-cell
![Page 6: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/6.jpg)
Outcomes of Sipuleucel-T :
• 4.1 months median survival benefit (25.8 months vs. 21.7 months).
• No time to objective disease progression benefit
• No survival difference detected between patients in the sipuleucel-T group who had T-cell responses against PAP and those who did not.
• Vaccine response no correlation with PSA response
![Page 7: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/7.jpg)
![Page 8: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/8.jpg)
Patient 1
Patient 9
![Page 9: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/9.jpg)
Blood
Cytokine
cocktail
Inject DCs
Intradermal
(3-5 x 106 cells/dose;
10 x bi-weekly doses)
QA/QC
FACS,
Endotoxin,
Mycoplasma
testing
DENDRITIC CELL VACCINE FOR COLORECTAL CANCER
![Page 10: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/10.jpg)
TREATMENT OF METASTATIC NASOPHARYNGEAL CARCINOMA WITH AUTOLOGOUS
DENDRITIC CELLS TRANSDUCED WITH ADENOVIRAL VECTOR (AD5F35) EXPRESSING
LATENT MEMBRANE PROTEIN (LMP)-1 AND LMP-2 GENES IN PATIENTS
A Phase II clinical trial, n=16
Blood
Cytokine
Cocktail
(TNFa,IL-1, IL-6, PGE2)
Ad5f35-DLMP1-
LMP2 vector
Intradermal
(3-5 x 106 cells/dose;
5 x bi-weekly doses)
![Page 11: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/11.jpg)
Baseline Date:
24/10/07Date: 5/3/08
PATIENT 004 – PARTIAL RESPONSE
![Page 12: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/12.jpg)
CD40L
MU
C-1
Ad-hMUC-1/ecdCD40L vaccine
DNA
CD40LMUC-1
Fusion protein expression & excretion
Infect
(e.g. fibroblasts)
Fusion protein uptake by DC
DC activation and antigen presentation
Antigen-specific T lymphocyte activation in Lymph nodes
Subcutaneous injection of vaccine
FIRST-IN-HUMAN CANCER VACCINE
MUC1-CD40L VACCINE ON AN ADENOVIRUS BACKBONE
![Page 13: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/13.jpg)
• Oncolytic Virus Therapy gets FDA Approval
![Page 14: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/14.jpg)
Oncolytic Viruses
![Page 15: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/15.jpg)
MORE CANCER MUTATIONS STIMULATE A BETTER IMMUNE RESPONSE
CANCER NEOANTIGENS
![Page 16: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/16.jpg)
Framework for identifying and targeting tumor neoantigens
Mark Yarchoan et al. Nature Reviews. 2017
![Page 17: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/17.jpg)
N = 13, 8 PATIENTS CANCER-FREE PRE-VACCINATION
![Page 18: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/18.jpg)
NEOANTIGEN DISCOVERY TO CLINIC
(A)
(B)2 synthetic RNA vaccine created, each encoding 5 selected peptide variants
![Page 19: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/19.jpg)
T CELL RESPONSES
%
(C) (D)
![Page 20: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/20.jpg)
Summary Points
• RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations
• All patients developed T cell responses against several vaccine neoepitopes up to high single-digit percentages
• 8 patients with no disease pre-vaccine remained cancer-free on long follow up
• Of 5 patients with existing disease, 2X had CR (one with anti-PD1 Tx), 1x had PR, 1X had Mixed Response and 1X had SD
![Page 21: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/21.jpg)
Summary Points
• Post-vaccination biopsies from two patients showed evidence of vaccine-induced T cell infiltration and neo-epitope-specific killing of autologous tumor cells
• One patient with metastatic disease developed a complete response to vaccination in combination with PD-1 blockade therapy even after rapid progression post-vaccine
• One patient with PR had a late relapse due to outgrowth of β2-microglobulin-deficient melanoma cells as an acquired resistance mechanism
![Page 22: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/22.jpg)
NEOANTIGEN PEPTIDE VACCINE
![Page 23: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/23.jpg)
NEOANTIGEN PEPTIDE VACCINE
• Vaccine targets 13 to 20 predicted personal tumour neoantigens, selected for HLA Class I binding
• CD4+ and CD8+ T cells targeted 97 unique neoantigens used across patients, and 60% T cell responses were CD4 T cell mediated
• Six vaccinated melanoma patients
• Two patients with disease pre-vaccine had CR in combo with anti-PD1 Tx, the four with no prior disease remained disease-free
![Page 24: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/24.jpg)
rational combinations with cancer vaccines
![Page 25: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/25.jpg)
BEWARE OF FALSE CANCER TREATMENT CLAIMS
![Page 26: CANCER VACCINES A PRIMER...Summary Points • RNA-based poly-neoepitope individualized mutanome vaccine against a variety of cancer mutations • All patients developed T cell responses](https://reader033.vdocuments.mx/reader033/viewer/2022050501/5f9362b18f881c6f4e68add9/html5/thumbnails/26.jpg)